{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:45:48Z","timestamp":1791999948438,"version":"4.4.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>The modified vaccinia virus Ankara (MVA) is approved for use as a smallpox and monkeypox virus vaccine and was also designed as a popular recombinant viral vector for vaccine development and gene therapy. However, the extensive genomes of poxviruses present a significant challenge for the development of recombinant viral vaccines; therefore, it is essential to establish a user-friendly <jats:italic>in vitro<\/jats:italic> reverse genetic system. We systematically assembled the 180-kb MVA genome into a five-plasmid system, facilitating one-step packaging of the MVA virus. The MVA rescued using this system exhibited similar virological characteristics, including host cell tropism, growth kinetics, plaque size, and viral particles, comparable to those of wild-type MVA. Immunization with rescued MVA intramuscularly or subcutaneously triggered robust-specific immune responses and conferred protection against lethal attacks by the ectromelia virus in mice. We also developed a recombinant MVA-Luc-eGFP virus, which served as a tool for screening antiviral compounds against poxviruses. The synthetic MVA system efficiently generates recombinant vaccines with robust immune responses. These findings provide a novel and fast method for engineering large viral genomes with more specialized structures and lay a foundation for the advancement of more rapid and effective viral vector vaccines.<\/jats:p>","DOI":"10.3389\/fmicb.2025.1572706","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T05:25:08Z","timestamp":1745558708000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Design and construction of a fast synthetic modified vaccinia virus Ankara reverse genetics system for advancing vaccine development"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhiqiang","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Busen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuyuan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shipo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S1473-3099(21)00128-6","article-title":"Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: A randomised, double-blind, controlled trial.","volume":"22","author":"Afolabi","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1006\/viro.1998.9123","article-title":"The complete genomic sequence of the modified vaccinia Ankara strain: Comparison with other orthopoxviruses.","volume":"244","author":"Antoine","year":"1998","journal-title":"Virology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1101\/sqb.1983.047.01.083","article-title":"Structure and replication of vaccinia virus telomeres.","volume":"47","author":"Baroudy","year":"1983","journal-title":"Cold Spring Harb. Symp. Quant. Biol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1099\/0022-1317-79-5-1159","article-title":"Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: Implications for use as a human vaccine.","volume":"79","author":"Blanchard","year":"1998","journal-title":"J Gen Virol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"6121","DOI":"10.1038\/s41467-020-19819-1","article-title":"Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform.","volume":"11","author":"Chiuppesi","year":"2020","journal-title":"Nat. Commun."},{"key":"B6","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/978-1-4939-9065-8_11","article-title":"Poxviruses as gene therapy vectors: Generating poxviral vectors expressing therapeutic transgenes.","volume":"1937","author":"Conrad","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e1638","DOI":"10.1371\/journal.pone.0001638","article-title":"Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).","volume":"3","author":"Cottingham","year":"2008","journal-title":"PLoS One"},{"key":"B8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.virol.2005.06.043","article-title":"The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection.","volume":"341","author":"Coulibaly","year":"2005","journal-title":"Virology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"520","DOI":"10.2144\/01303st02","article-title":"Oligonucleotide-mediated, PCR-independent cloning by homologous recombination.","volume":"30","author":"DeMarini","year":"2001","journal-title":"Biotechniques"},{"key":"B10","doi-asserted-by":"publisher","first-page":"12415","DOI":"10.1073\/pnas.192420599","article-title":"Cloning the vaccinia virus genome as a bacterial artificial chromosome in Escherichia coli and recovery of infectious virus in mammalian cells.","volume":"99","author":"Domi","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"B11","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1073\/pnas.262668999","article-title":"Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines.","volume":"100","author":"Drexler","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"B12","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/nm1261","article-title":"Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus.","volume":"11","author":"Edghill-Smith","year":"2005","journal-title":"Nat. Med."},{"key":"B13","first-page":"283","article-title":"[An attenuated strain of vaccinia virus (MVA). Successful intramuscular immunization against vaccinia and variola (author\u2019s transl)].","volume":"230","author":"Hochstein-Mintzel","year":"1975","journal-title":"Zentralbl. Bakteriol. Orig. A"},{"key":"B14","first-page":"104","article-title":"[Virulence and immunogenicity of a modified vaccinia virus (strain MVA) (author\u2019s transl)].","volume":"144","author":"Hochstein-Mintzel","year":"1972","journal-title":"Zeitschrift Immunitatsforschung Exp. Klinische Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"126427","DOI":"10.1016\/j.vaccine.2024.126427","article-title":"A multivalent RSV vaccine based on the modified vaccinia Ankara vector shows moderate protection against disease caused by RSV in older adults in a phase 3 clinical study.","volume":"42","author":"Jordan","year":"2024","journal-title":"Vaccine"},{"key":"B16","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/S1473-3099(20)30248-6","article-title":"Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: An open-label, phase 1 trial.","volume":"20","author":"Koch","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"7415","DOI":"10.1073\/pnas.79.23.7415","article-title":"Vaccinia virus: A selectable eukaryotic cloning and expression vector.","volume":"79","author":"Mackett","year":"1982","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"B18","first-page":"375","article-title":"[The smallpox vaccination strain MVA: Marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author\u2019s transl)].","volume":"167","author":"Mayr","year":"1978","journal-title":"Zentralbl. Bakteriol. B"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1086\/421266","article-title":"Modified vaccinia Ankara: Potential as an alternative smallpox vaccine.","volume":"38","author":"McCurdy","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"a010199","DOI":"10.1101\/cshperspect.a010199","article-title":"Poxvirus DNA replication.","volume":"5","author":"Moss","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"5540","DOI":"10.1016\/j.cell.2024.08.043","article-title":"Comparison of protection against mpox following mRNA or modified vaccinia Ankara vaccination in nonhuman primates","volume":"187","author":"Mucker","year":"2024","journal-title":"Cell"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e0188453","DOI":"10.1371\/journal.pone.0188453","article-title":"Construction of an infectious horsepox virus vaccine from chemically synthesized DNA fragments.","volume":"13","author":"Noyce","year":"2018","journal-title":"PLoS One"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1264323","DOI":"10.3389\/fimmu.2023.1264323","article-title":"Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates.","volume":"14","author":"P\u00e9rez","year":"2023","journal-title":"Front. Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1817307","article-title":"Phase 3 efficacy trial of modified vaccinia ankara as a vaccine against smallpox.","volume":"381","author":"Pittman","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"734","DOI":"10.15585\/mmwr.mm7122e1","article-title":"Use of JYNNEOS (Smallpox and monkeypox vaccine, live, nonreplicating) for preexposure vaccination of persons at risk for occupational exposure to orthopoxviruses: Recommendations of the advisory committee on immunization practices - United States, 2022.","volume":"71","author":"Rao","year":"2022","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"B26","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/0378-1119(83)90163-4","article-title":"Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA.","volume":"25","author":"Smith","year":"1983","journal-title":"Gene"},{"key":"B27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41541-023-00640-y","article-title":"Synthetic multiantigen MVA vaccine COH04S1 and variant-specific derivatives protect Syrian hamsters from SARS-CoV-2 Omicron subvariants.","volume":"8","author":"Wussow","year":"2023","journal-title":"NPJ Vaccines"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1007\/s11427-023-2515-0","article-title":"Rational design of a single-component mRNA vaccine against orthopoxvirus and SARS-CoV-2.","volume":"67","author":"Yang","year":"2024","journal-title":"Sci. China Life Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1080\/14760584.2023.2296937","article-title":"Immunogenicity and safety of ebolavirus vaccines in healthy adults: A systematic review and meta-analysis of randomized controlled trials.","volume":"23","author":"Yin","year":"2024","journal-title":"Expert. Rev. Vaccines"}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2025.1572706\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T05:25:09Z","timestamp":1745558709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2025.1572706\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":29,"alternative-id":["10.3389\/fmicb.2025.1572706"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2025.1572706","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,25]]},"article-number":"1572706"}}